On April 22, 2026 Sironax, a global clinical-stage biotechnology company developing transformative therapies for neurodegenerative, inflammatory and immunological, metabolic, and rare diseases, reported the selection of an abstract for presentation in a poster session at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) annual meeting. The meeting will take place from May 29 to June 2 in Chicago, IL.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Presentation details are below:

Poster Title: SARM1 Inhibition to Prevent Chemotherapy-Induced Peripheral Neuropathy: Translational and Early Clinical Evaluation of SIR2501
Poster Board: 131
Abstract #: 12148
Date/Time: May 30, 2026, 1:30-4:30 PM CDT

(Press release, Sironax, APR 22, 2026, View Source [SID1234664711])